MARCKS and metastatic neoplasm: Given that the MANS peptide has also been shown to inhibit neutrophil, macrophages and mesenchymal stem cell migration [16]–[18] the results reported here provide further evidence for the concept that inhibiting MARCKS function may be a valuable novel therapeutic approach for various diseases associated with exacerbated cell migration, such as inflammation, injury/repair and metastatic disease.